

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF ART UNIT: 1614
HOLMES, DAVID GRENVILLE ET AL. EXAMINER: ROYDS, LESLIE A
INTERNATIONAL APPLICATION NO: PCT/EP03/05762
FILED: JUNE 02, 2003
U.S. APPLICATION NO: 10/516633
35 USC §371 DATE: JANUARY 19, 2005
FOR: USE OF SUBSTITUTED CYANOPYRROLIDINES AND
COMBINATION PREPARATIONS CONTAINING THEM FOR
TREATING HYPERLIPIDEMIA AND ASSOCIATED DISEASES

MS: Amendment
Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir'

This paper is being filed:

supplemental to the Information Disclosure Statement filed April 22, 2009.

If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134 in the name of Novartis.

- This Information Disclosure Statement is being filed in accordance with 37 C.F.R. §1.97(c) or 37 C.F.R. §1.97(d).
- A letter for payment of fee set forth in 37 C.F.R. §1.17(p) is enclosed.


In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

Copies of the references are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Certificate under 37 C.F.R. §1.97(e)(1): I, the undersigned Attorney, hereby certify that each item of information contained in the Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Information Disclosure Statement.

Respectfully submitted,



Cozette M. McAvoy
Attorney for Applicant
Reg. No. 60,457

Novartis Pharmaceuticals Corporation
One Health Plaza, Bldg. 101
East Hanover, NJ 07936
(862) 778-9273

Date: *3rd August 2010*